Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 735.77% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 100.25M.
Fairly Valued
The company’s latest PE is -12.27, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 49.25M shares, decreasing 4.25% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 2.18M shares of this stock.